Fund profile by ISIN IE00BF0H7608
L&G Pharma Breakthrough UCITS ETF
Research L&G Pharma Breakthrough UCITS ETF by ISIN IE00BF0H7608: TER 0.49%, domicile Ireland, and 1-year price performance +33.3%.
ISINIE00BF0H7608
TER0.49%
DomicileIreland
Distribution policy—
Index—
Fund size22M
Holdings—
1-year price performance+33.3%
Exchange listings and tradability
| Ticker | Exchange | Currency | Country | Avg daily turnover | Avg daily shares |
|---|---|---|---|---|---|
| ETLI.DE | XETRADefault at German brokers | EUR | Ireland | €62K | 4,742 |
| BIGT.L | LSE | GBX | Ireland | €13K | 1,045 |
| BIOT.MI | ETFP | EUR | Ireland | €13K | 1,009 |
| BIOT.AS | XAMS | EUR | Ireland | €9K | 745 |
| BIOT.SW | SW | CHF | Ireland | €5K | 417 |
| BIOT.L | LSE | USD | Ireland | €5K | 398 |
Avg daily turnover is the 90-day average, converted to euros so venues in different currencies can be compared; avg daily shares is the same window in units. The most traded listing is shown first. This fund trades on a German exchange. As of 2026-08-28.
Largest holdings
The 10 largest holdings make up 35.92% of the fund. As of 2026-08-14.
| Holding | Symbol | Weight |
|---|---|---|
| Travere Therapeutics Inc Ordinary Shares | TVTX | 5.17% |
| Xencor Inc | XNCR | 4.50% |
| Ligand Pharmaceuticals Inc | LGND | 3.59% |
| Xeris Biopharma Holdings Inc | XERS | 3.51% |
| Jazz Pharmaceuticals PLC | JAZZ | 3.50% |
| Royalty Pharma PLC Class A | RPRX | 3.24% |
| Incyte Corp | INCY | 3.14% |
| Mirum Pharmaceuticals Inc | MIRM | 3.09% |
| BridgeBio Pharma Inc | BBIO | 3.09% |
| Halozyme Therapeutics Inc | HALO | 3.09% |
Performance is the historical price return of the representative listing. Distributions are excluded and past performance is not a forecast.